$18m cap,rare solid balance sheet vs $1B + market: http://www.mordorintelligence.com/industry-reports/ovarian-cancer-diagnostics-and-therapeutics-market?gclid=CPLBv_2epc0CFTMo0wodS5ALxg Assets/debt ratio=12 very solid,RARE,Net Assets(total assets minus total liabilities)= $22m. vs $18m cap. Co. received a Fast Track + Orphan Drug. FDA very impressed.this is a $10+ stock on the works imo.